PTLF (Petlife Pharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2018)


What is Petlife Pharmaceuticals LT-Debt-to-Total-Asset?

Petlife Pharmaceuticals PTLF LT-Debt-to-Total-Asset is 0.00 as of Feb. 2018.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Petlife Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Feb. 2018 was 0.00.

Petlife Pharmaceuticals's long-term debt to total assets ratio stayed the same from Feb. 2017 (0.00) to Feb. 2018 (0.00).

Petlife Pharmaceuticals  (OTCPK:PTLF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Petlife Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Petlife Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals LT-Debt-to-Total-Asset Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Petlife Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Petlife Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2017 is calculated as

LT Debt to Total Assets (A: Aug. 2017 )=Long-Term Debt & Capital Lease Obligation (A: Aug. 2017 )/Total Assets (A: Aug. 2017 )
=0/0.055
=

Petlife Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2018 is calculated as

LT Debt to Total Assets (Q: Feb. 2018 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2018 )/Total Assets (Q: Feb. 2018 )
=0/0.008
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Petlife Pharmaceuticals (PTLF) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2018. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Petlife Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00.
How does Petlife Pharmaceuticals' LT-Debt-to-Total-Asset compare to PCYN and YBAO?
Petlife Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Petlife Pharmaceuticals and its competitors. Petlife Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.